ORMP — Oramed Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $102.11m
- -$9.85m
- $1.34m
- 48
- 31
- 86
- 55
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.4 | -11.5 | -23 | -37.8 | 5.09 |
Depreciation | |||||
Non-Cash Items | 1.12 | 2.22 | 3.05 | 10.7 | -12.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.29 | -3.16 | -1.31 | -0.943 | -2.7 |
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -12.9 | -12.4 | -21.2 | -27.9 | -10.3 |
Capital Expenditures | -0.015 | -0.082 | -0.375 | -0.496 | -0.254 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 11.3 | 4.71 | -23.4 | 30.7 | -72.8 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 11.3 | 4.63 | -23.8 | 30.2 | -73 |
Financing Cash Flow Items | — | — | 1.5 | -0.783 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0 | 23.8 | 103 | 10.8 | 52 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.67 | 16 | 57.9 | 13 | -31.4 |